MediciNova, Inc.
NASDAQ: MNOV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yuichi Iwaki
- Employees
- 13
- Headquarters
- La Jolla, United States
- IPO year
- 2006
- Market cap
- $65.5M
- Website
- https://www.medicinova.com
Loading MNOV…
Loading profile data…Frequently asked questions about MNOV
What does MediciNova, Inc. (MNOV) do?
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, cur...
Where does MNOV trade?
MediciNova, Inc. (MNOV) trades on the NASDAQ Global Market.
What sector is MNOV in?
MediciNova, Inc. (MNOV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MediciNova, Inc.?
Yuichi Iwaki is the chief executive officer of MediciNova, Inc. (MNOV).
Where is MediciNova, Inc. headquartered?
MediciNova, Inc. is headquartered in United States.
Does MNOV pay a dividend?
MediciNova, Inc. (MNOV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MNOV go public?
MediciNova, Inc. (MNOV) completed its initial public offering in 2006.